- Home
- GSL vs CVAC Comparison
GSL vs CVAC Comparison
Compare GSL & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- CVAC
- Stock Information
- Founded
- GSL 2007
- CVAC 2000
- Country
- GSL Greece
- CVAC Germany
- Employees
- GSL N/A
- CVAC N/A
- Industry
- GSL Marine Transportation
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- GSL Consumer Discretionary
- CVAC Health Care
- Exchange
- GSL Nasdaq
- CVAC Nasdaq
- Market Cap
- GSL 1.0B
- CVAC 1.2B
- IPO Year
- GSL 2006
- CVAC 2020
- Fundamental
- Price
- GSL $30.51
- CVAC $5.38
- Analyst Decision
- GSL Strong Buy
- CVAC Hold
- Analyst Count
- GSL 1
- CVAC 3
- Target Price
- GSL $33.00
- CVAC $6.83
- AVG Volume (30 Days)
- GSL 328.6K
- CVAC 422.9K
- Earning Date
- GSL 11-05-2025
- CVAC 11-12-2025
- Dividend Yield
- GSL 6.88%
- CVAC N/A
- EPS Growth
- GSL 19.05
- CVAC N/A
- EPS
- GSL 10.76
- CVAC 1.01
- Revenue
- GSL $730,277,000.00
- CVAC $599,540,810.00
- Revenue This Year
- GSL $4.58
- CVAC N/A
- Revenue Next Year
- GSL N/A
- CVAC $23.40
- P/E Ratio
- GSL $2.83
- CVAC $5.35
- Revenue Growth
- GSL 4.04
- CVAC 675.15
- 52 Week Low
- GSL $17.73
- CVAC $2.37
- 52 Week High
- GSL $33.08
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- GSL 60.94
- CVAC 49.44
- Support Level
- GSL $27.81
- CVAC $5.35
- Resistance Level
- GSL $28.96
- CVAC $5.41
- Average True Range (ATR)
- GSL 0.69
- CVAC 0.04
- MACD
- GSL 0.29
- CVAC -0.00
- Stochastic Oscillator
- GSL 94.44
- CVAC 50.00
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.